头孢丙烯治疗呼吸道感染的临床研究

Clinical study of cefprozil in treatment of respiratory tract infections

目的 :评价国产头孢丙烯片剂治疗呼吸道感染的疗效与安全性。方法 :头孢丙烯片与头孢克洛胶囊随机对照治疗下呼吸道感染 10 1例 ,头孢丙烯组 5 1例 (男性 33例 ,女性 18例 ,年龄 5 0a±s 13a) ,头孢克洛组 5 0例 (男性 2 9例 ,女性 2 1例 ,年龄4 9a± 15a)剂量分别均为 5 0 0mg ,po ,bid及tid ;另用头孢丙烯片 5 0 0mg ,po ,qd开放治疗上呼吸道感染 5 5例 ;疗程均 7～ 14d。结果 :头孢丙烯和头孢克洛治疗下呼吸道感染的有效率分别为 94 %及92 % ,细菌清除率均为 93% ,不良反应发生率分别为 10 %及 8% ,2组比较差异均无显著意义 ,P >0 .0 5。头孢丙烯开放治疗上呼吸道感染 5 5例的有效率为 94 % ,细菌清除率为 90 % ,不良反应发生率为4 %。结论 :头孢丙烯片剂治疗呼吸道感染疗效确切 。

AIM: To evaluate the efficacy and safety of domestic cefprozil tablet in the treatment of respiratory tract infections. METHODS: A total of one hundred and one patients with lower respiratory tract infections were randomly divided into two groups:cefprozil group fifty-one patients (M 33,F 18; age 50 a±s13 a) were treated with cefprozil 500 mg,po,bid, and cefaclor group fifty patients (M 29, F 21; age 49 a±15 a)were treated with cefaclor 500 mg, po, tid for 7-14 d. Fifty-five patients with upper respiratory tract infections in open group were treated with cefprozil 500 mg, po, qd for 7-14 d. RESULTS: In the randomized controlled study, the clinical efficacy rate of cefprozil and cefaclor was 94 %(48/51) and 92 %(46/50), respectively.The bacterial elimination rate was 93%(41/44 and 39/42) in both groups. The adverse reaction occurrence rate was 10 %(5/52) and 8 %(4/51), respectively. There was no statistically significant difference between the above data of two groups. The clinical effective rate and bacterial elimination rate of cefprozil in the treatment of upper respiratory tract infections was 94 %(52/55) and 90 %(44/49), respectively. The adverse reaction rate was 4 %(2/55). CONCLUSION: Cefprozil is effective and safe in the treatment of respiratory tract infections.